Taken together, in addition to the possibility of E5 as a valuable drug candidate, the present study further supports the notion that targeted inhibition of PDGFRα is a promising therapeutic strategy for HCC. The gene discussed is PDGFRA; the disease is hepatocellular carcinoma.